Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis
NCT06457425Phase 2Active, not recruiting
- Sponsor
- Zenitar
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flonoltinib in myelofibrosis (MF), sponsored by Zenitar. Started May 2024; status: active, not recruiting.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06457425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457425.